ABBVIE
🇫🇷France
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 55
- Registration Number
- NCT02668640
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 413
- Registration Number
- NCT02654054
- Locations
- 🇺🇸
Houston Ctr for Clin Research /ID# 149149, Sugar Land, Texas, United States
🇺🇸Fellows Research Alliance, Inc /ID# 139655, Savannah, Georgia, United States
🇺🇸University of California, Los Angeles /ID# 144107, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT02651194
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 146
- Registration Number
- NCT02642432
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
Completed
- Conditions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 394
- Registration Number
- NCT02640547
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 304
- Registration Number
- NCT02640482
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02640833
- Locations
- 🇺🇸
Site Reference ID/Investigator# 148562, Harvey, Illinois, United States
🇺🇸Site Reference ID/Investigator# 147922, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 506
- Registration Number
- NCT02640157
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary
Completed
- Conditions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 244
- Registration Number
- NCT02636608
The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 121
- Registration Number
- NCT02636595
© Copyright 2024. All Rights Reserved by MedPath